Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI), a part of the National Institutes of Health (NIH).
Under a Cooperative Research and Development Agreement (CRADA), the National Eye Institute and Curative Biotechnology, Inc. will collaborate to evaluate Curative’s proprietary ocular metformin formulation in clinical studies for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease.
Emily Y. Chew, M.D. is the Director of the Division of Epidemiology and Clinical Applications (DECA) at the National Eye Institute, the National Institutes of Health in Bethesda, Maryland. She is also the Chief of the Clinical Trials Branch in the division. Her research interest includes phase I/II clinical trials and epidemiologic studies in retinovascular diseases such as age-related macular degeneration, diabetic retinopathy, and other ocular diseases. She is the author of more than 200 research articles based on her studies of retinal disease.
About Macular Degeneration
Numerous diseases cause degeneration of the macular tissue in the retina resulting in vision loss or blindness. Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness in the United States and worldwide. As AMD advances through early to intermediate and late stages (Geographic Atrophy, “GA”), progressive degeneration of macular cells may lead to loss of central vision in one or both eyes. There is no cure for AMD, and currently, very little can be done to slow its progression. Potential treatments, such as the metformin therapy proposed under this CRADA study, are being tested to address the unmet need for AMD therapies and possibly another retinal degenerative disease.
About National Institutes of Health (NIH)
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.
NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address the special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.
Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is focused on identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro-oncology, and degenerative eye disease. The Company’s pipeline includes IMT504, CURB906, and Metformin Reformulation. IMT504 is a novel immune therapy to treat rabies and an adjuvant for vaccines; CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation is targeting the treatment of degenerative eye disease.
Curative Biotech is a development-stage biomedical company focusing on novel treatments for rare or currently unmet medical needs. Curative Biotech is focused on therapies with potentially accelerated development paths resulting from either the disease, the nature of the therapeutic itself, or the stage of clinical development.
This article was shared with Prittle Prattle News as a Press Release.
